BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC (BELOXAN)

Inclusion Criteria:

• Stage IIIB/IV or Relapsed NSCLC
• Age >= 18 years
• At least one measurable lesion by RECIST (version 1.1)
• ECOG PS 0, 1, 2

• Hematologic profile

  • Hgb > 8 g/dL, ANC >= 2,000/m3, Platelet >= 100,000/m3

• Hepatic profile

  • Total bilirubin <= 1.5 x upper normal value
  • Transaminases <= 3 x upper normal value <= 5 x upper normal value in case of liver metastasis
• Creatinine <= 1.5mg/dL
• Patients should be recovered from toxicities of previous treatment.
• Written informed consent by patient or surrogates

Exclusion Criteria:

• Patients who had been previously treated with chemotherapy for NSCLC
• Active infection requiring antibiotics treatment
• Prior diagnosis of other malignancy except radically treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix
• Peripheral neuropathy >= grade 2 by NCI CTCAE 4.0
• Uncontrolled hypertension, Acute myocardial infarction within 6 months Unstable angina, Congestive heart failure >= NYHA grade 2 Uncontrolled significant arrhythmia
• Patients who entered other clinical trials within 4 weeks
• Pregnant or lactating women. women with child bearing age who are not willing to a contraceptive measure